<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04723342</url>
  </required_header>
  <id_info>
    <org_study_id>ALL-MB 2019 Pilot</org_study_id>
    <nct_id>NCT04723342</nct_id>
  </id_info>
  <brief_title>Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot</brief_title>
  <official_title>Treatment of Children and Adolescents With Primary B-precursor Acute Lymphoblastic Leukemia With Combination Chemotherapy and Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      THE PURPOSE OF THE STUDY is to optimize the therapy of patients with primary B-cell precursor&#xD;
      acute lymphoblastic leukemia (BCP-ALL) by including monoclonal bispecific antibodies in&#xD;
      post-induction treatment with simultaneous reduction of chemotherapy.&#xD;
&#xD;
      QUESTIONS AND OBJECTIVES OF THE STUDY:&#xD;
&#xD;
        -  to determine the efficacy and feasibility of chemotherapy and immunotherapy combination&#xD;
           in comparison with standard PCT in children and adolescents with newly diagnosed&#xD;
           BCP-ALL;&#xD;
&#xD;
        -  to determine the safety and toxicity of chemotherapy and immunotherapy combination in&#xD;
           comparison with standard PCT in children and adolescents with newly diagnosed BCP-ALL;&#xD;
&#xD;
        -  to determine the possibility of chemotherapy reducing when immunotherapy is included in&#xD;
           the treatment regimen without loss of effectiveness;&#xD;
&#xD;
        -  to determine the possibility of reducing the maintenance therapy duration to 1 year when&#xD;
           immunotherapy is included in the treatment regimen without loss of effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal residual disease level</measure>
    <time_frame>On the last day of the blinatumomab course, on average at 11 weeks of protocol</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal residual disease level</measure>
    <time_frame>6 months after starting maintenance therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal residual disease level</measure>
    <time_frame>1 year after starting maintenance therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>3 years after study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>5 years after study start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>3 years after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>5 years after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission death rate</measure>
    <time_frame>3 years after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission death rate</measure>
    <time_frame>5 years after study start</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Blinatumomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation therapy with Blinatumomab administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day&#xD;
1 course after induction treatment</description>
    <arm_group_label>Blinatumomab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        This study included patients with B-cell precursor ALL (BCP-ALL) diagnosed or confirmed in&#xD;
        one of the clinics participating in the study. Also following criteria should be considered&#xD;
        at the diagnosis for each case:&#xD;
&#xD;
          1. Age at diagnosis at 1 to 18 years.&#xD;
&#xD;
          2. The start of induction therapy within a time interval of study recruitment phase.&#xD;
&#xD;
          3. The diagnosis of BCP-ALL is to be proved by the morphological, cytochemical, and&#xD;
             immunological analysis of tumor cells in bone marrow in the reference laboratories of&#xD;
             Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and&#xD;
             Immunology (D. Rogachev NMRCPHOI).&#xD;
&#xD;
          4. CD19 expression on tumor cells.&#xD;
&#xD;
          5. Informed consent of the patient parents (guardians)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any non-compliance with the inclusion criteria.&#xD;
&#xD;
          2. ALL is a second malignancy.&#xD;
&#xD;
          3. There is severe concomitant disease, which significantly impedes chemotherapy protocol&#xD;
             (such as multiple malformations, heart diseases, metabolic disorders, etc.);&#xD;
&#xD;
          4. The patient was treated before for a long time with cytotoxic drugs.&#xD;
&#xD;
          5. Initial CNS (central nervous system) involvement (status CNSII or CNSIII).&#xD;
&#xD;
          6. Initial leukocyte count ≥100×109/L (except for patients with significant&#xD;
             translocations).&#xD;
&#xD;
          7. Patients not achieved cytological remission after induction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander I. Karachunskiy, Professor,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander I. Karachunskiy, Professor,MD</last_name>
    <phone>+7-926-218-84-09</phone>
    <email>info@mbstudy.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia V. Roumiantseva, MD, PhD</last_name>
    <phone>+7-903-730-39-78</phone>
    <email>j.roumiantseva@mbstudy.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dmitry Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Oncology named after N.N. Blokhin</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Russian Children's Clinic Hospital; Pirogov Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Children</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Blinatumomab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blinatumomab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

